bolsters

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfrontNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is…

2 months ago
BioCina and NovaCina Merger Bolsters Global CDMO IndustryBioCina and NovaCina Merger Bolsters Global CDMO Industry

BioCina and NovaCina Merger Bolsters Global CDMO Industry

ADELAIDE, South Australia and PERTH, Western Australia, Jan. 13, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina…

3 months ago